Advancing addiction treatment using neuromodulation: a rTMS enhanced CBT trial - Advancing addiction treatment

Academisch Medisch Centrum0 个研究点目标入组 80 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•The recruitment of participants will take place as follows. Practitioners at
•Jellinek will inform patients about our study and we will give presentations at
•Jellinek to inform patients about this study. If somebody is willing to
•participate in the study, we will personally visit them at Jellinek and explain
•the entire procedure. Furthermore they will receive an information letter by
•email to make sure they can read the information again carefully. If they are
•still interested in participation they will sign informed consent and we will
•perform screening for inclusion and exclusion criteria. Demographics,
•psychiatric disorders (MINI), TMS contraindications and MR contraindications
•are questioned to make sure that the individual can participate.
•If a participant meets any of the exclusion criteria that they are excluded
•from participation in this study. , Inclusion criteria
•- Men and women.
•- Age between 25-65.
•- Recent DSM-V diagnosis (mild, moderate and severe) of alcohol abuse (<4
•months after detox).
•- Currently in treatment (>3 weeks after detox) and will be in treatment during
•the entire stimulation period (2 weeks after inclusion).
•- Sufficient speaking and understanding of Dutch language.

•Exclusion criteria
•- A DSM-V diagnosis of schizophrenia or another psychotic disorder, personality
•disorder or sleep disorder.
•- TMS contraindications: history of epileptic seizures or epilepsy in a first
•degree relative, irregular sleep/ wake rhythm.
•- MR contraindications (only relevant for the 40 participants who will undergo
•MR scanning): metal implants, claustrophobia.

发起方